Edmond DE Rothschild Holding S.A. trimmed its holdings in Geron Corporation (NASDAQ:GERN – Free Report) by 48.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,200,000 shares of the biopharmaceutical company’s stock after selling 1,130,000 shares during the quarter. Edmond DE Rothschild Holding S.A. owned 0.19% of Geron worth $1,476,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also recently bought and sold shares of GERN. BlackRock Inc. bought a new position in shares of Geron during the second quarter valued at $62,868,000. Eversept Partners LP grew its stake in shares of Geron by 6.7% during the first quarter. Eversept Partners LP now owns 18,834,883 shares of the biopharmaceutical company’s stock worth $28,064,000 after purchasing an additional 1,174,900 shares during the period. Nantahala Capital Management LLC bought a new stake in Geron in the second quarter valued at approximately $15,648,000. Candriam S.C.A. raised its position in shares of Geron by 42.8% during the third quarter. Candriam S.C.A. now owns 7,982,968 shares of the biopharmaceutical company’s stock worth $9,855,000 after purchasing an additional 2,393,786 shares during the period. Finally, Pale Fire Capital SE lifted its stake in Geron by 8.6% in the second quarter. Pale Fire Capital SE now owns 5,307,204 shares of the biopharmaceutical company’s stock valued at $6,793,000 after buying an additional 418,900 shares in the last quarter. Institutional investors own 73.71% of the company’s stock.
Geron Price Performance
Geron stock opened at $0.87 on Friday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 4.61 and a current ratio of 6.31. The stock has a market capitalization of $560.49 million, a P/E ratio of -10.88 and a beta of 0.62. Geron Corporation has a 52 week low of $0.84 and a 52 week high of $2.01. The stock has a fifty day moving average of $1.13 and a 200-day moving average of $1.39.
Analysts Set New Price Targets
Check Out Our Latest Stock Report on GERN
Geron Company Profile
Geron Corporation is a biopharmaceutical company focused on developing and commercializing therapies for blood disorders and cancers. Its lead product, Rytelo (imetelstat), is a telomerase inhibitor approved in the United States to treat certain adults with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia. Geron continues to develop imetelstat for potential use in other hematologic conditions. The company was founded in 1990 and is headquartered in Foster City, California.
See Also
- Five stocks we like better than Geron
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding GERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Geron Corporation (NASDAQ:GERN – Free Report).
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.
